Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Jungfraubahn...

Jungfraubahn Holding's (VTX:JFN) stock is up by a considerable 28% over the past three months. Since the market usually...

Key Insights Jungfraubahn Holding's estimated fair value is CHF486 based on 2 Stage Free Cash Flow to Equity Current...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...

Jungfraubahn Holding (SWX:JFN) shares have drawn some attention lately after a steady run over the past month, climbing about 9%. Investors are taking note, especially as the company shows consistent profit growth. See our latest analysis for Jungfraubahn Holding. This latest climb builds on a year where Jungfraubahn Holding has delivered steady gains for shareholders, underscored by a 12-month total shareholder return of 34%. Momentum appears to be accelerating as recent gains signal...

By buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

It's been a good week for Jungfraubahn Holding AG ( VTX:JFN ) shareholders, because the company has just released its...